Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1173 - Survival is associated with circulating cytokine levels in metastatic testicular germ cell tumors


10 Oct 2016


Poster display


Daniela Svetlovska


Annals of Oncology (2016) 27 (6): 526-544. 10.1093/annonc/mdw392


D. Svetlovska1, V. Miskovska2, D. Cholujova3, P. Gronesova3, S. Cingelova4, M. Chovanec5, Z. Sycova-Mila5, J. Obertova6, P. Palacka6, J. Rajec6, K. Kalavska7, V. Usakova8, J. Luha9, D. Ondrus2, S. Spanik10, J. Mardiak6, M. Mego11

Author affiliations

  • 1 Clinical Trials; Translational Research Unit, National Cancer Institute; Faculty of Medicine, Comenius University, 83310 - Bratislava/SK
  • 2 1st Department Of Oncology, Faculty of Medicine and St. Elisabeth Cancer Institute, Bratislava/SK
  • 3 Laboratory Of Tumor Immunology, Cancer Research Institute, Slovak Academy of Sciences, Bratislava/SK
  • 4 Oncohematology Clinic, National Cancer Institute, Bratislava/SK
  • 5 Clinical Oncology, National Cancer Institute, Bratislava/SK
  • 6 Clinical Oncology; 2nd Department Of Oncology, National Cancer Institute; Faculty of Medicine, Comenius University, Bratislava/SK
  • 7 Translational Research Unit, faculty of Medicine, Comenius University, Bratislava/SK
  • 8 Internal Medicine, St. Elisabeth Cancer Institute, Bratislava/SK
  • 9 Institute Of Medical Biology, Genetics And Clinical Genetics, faculty of Medicine, Comenius University, Bratislava/SK
  • 10 1st Department Of Oncology; Internal Medicine, Faculty of Medicine and St. Elisabeth Cancer Institute; St. Elisabeth Cancer Institute, Bratislava/SK
  • 11 Clinical Oncology; Translational Research Unit; 2nd Department Of Oncology, National Cancer Institute; Faculty of Medicine, Comenius University, Bratislava/SK


Abstract 1173


Cytokines are the communicators of immune system and are involved in almost all immune responses. They have an important role in cancer pathogenesis. The aim of this study was to investigate the association between plasma cytokines and patient's/tumor characteristics and prognosis in metastatic chemonaive testicular germ cell tumors (TGCTs).


The study population consisted of 92 chemonaive metastatic TGCTs patients, enrolled between July 2010 and March 2014. We analyzed 51 plasma cytokines at baseline before chemotherapy administration (n = 92) and on cycle 1 day 22 (n = 55) using multiplex bead arrays. Patients were treated with at least one cycle of cisplatin-based chemotherapy. Circulating cytokine levels were correlated with tumor characteristics, progression-free and overall survival as well.


Median age was 32.4 (range 18.4-65.4) years, median follow up was 33.2 month (range 0.1-54.8). Disease progression experienced 10.9 % and 7.6 % of patients died. Several baseline cytokines positively correlated with histology, disease stage, localization of metastases. Elevated baseline levels of IFN-alpha 2, IL-2R alpha, IL-16, HGF, MCP-3 significantly correlated with worse progression-free survival (PFS) and overall survival (OS) as well, SCGF-beta only with worse OS. Higher levels of IL-12p40 measured on day 22 cycle 1 correlated with shorter PFS and OS.


The present study found out significant associations between circulating cytokines and prognosis and tumour/patient's characteristics in metastatic TGCTs. Our findings suggest, that plasma cytokines could be considered as biomarker for identification of high risk patients. In addition, new treatment approaches targeted for relevant cytokine should be investigated.

Clinical trial identification

Not applicable

Legal entity responsible for the study

National Cancer Institute, Bratislava, Slovak Republic


Slovak Research and Development Agency


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings